Rilonacept
IL-1 trap (soluble decoy receptor)
- Response rate
- Moderate
- Onset
- Days-weeks
- Route
- SC weekly
- Line
- 3rd
- IgM effect
- Reduces SAA/CRP
Evidence summary
Dimeric fusion protein that traps IL-1alpha and IL-1beta. Evaluated in clinical trials for FMF. Less commonly used than anakinra or canakinumab. Included in Cochrane systematic review of FMF treatments.
Molecular targets (1)
| Molecule | Role | Expression | Evidence |
|---|---|---|---|
| IL-1β | Central effector cytokine | Elevated | established |